Enlivex Therapeutics Ltd

NASDAQ:ENLV  
5.84
+0.06 (+1.04%)
Products, Regulatory

Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering Treatment Of Sepsis Patients With Allocetra

Published: 12/06/2021 15:12 GMT
Enlivex Therapeutics Ltd (ENLV) - Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Treatment of Sepsis Patients With Allocetra.
Enlivex Therapeutics Ltd - Expects That This New Patent Will Be Issued in the United States in Early 2022.
Enlivex Therapeutics - Patent Will Provide Added Ip Protection in U.S. at Least Through 2036 With Claims Covering Use of Allocetra.
Further Company Coverage: Enlv.
Ta.
((reuters.
Briefs@thomsonreuters.
Com;)).